Complement activation in acute coronary syndromes

Area of Science:

• Cardiovascular Medicine
• Immunology
• Biochemistry

Background:

• The complement system, a key component of innate immunity, is increasingly implicated in cardiovascular disease.
• Understanding complement's role in ischemic heart disease is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate complement activation in patients with acute coronary syndromes (ACS).
• To correlate complement activation levels with markers of myocardial injury.
• To differentiate complement activation patterns across various ACS subtypes and stable angina.

Main Methods:

• Assessed plasma levels of Complement 3 (C3), Complement 4 (C4), C-reactive protein (CRP), troponin I (TnI), and creatine kinase MB (CK-MB) in 152 subjects.
• Included patients with acute myocardial infarction (AMI), non-Q wave MI (NQMI), unstable angina (UAP), stable angina (SA), and healthy controls.
• Collected blood samples at multiple time points for ACS patients and single measurements for stable angina and control groups.

Main Results:

• Significantly elevated C3 and C4 levels were observed in patients with AMI and NQMI compared to SA and controls.
• Patients with SA and UAP also showed higher C3 and C4 levels than controls.
• Complement levels (C3, C4) correlated positively with myocardial injury markers (CK-MB, TnI) and CRP in ACS patients.

Conclusions:

• Plasma C3 and C4 levels are elevated in ACS and SA, indicating complement activation in ischemic heart disease.
• The degree of complement activation correlates with the extent of myocardial necrosis.
• Complement activation is a significant factor in the pathophysiology of acute coronary syndromes.